Current Approaches for the Management of Multiple Sclerosis – A Review

Lakhwinder Singh a, Sabina Yasmin a and Rajiv Sharma a*

a University Institute of Pharma Sciences, Chandigarh University, Mohali, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i52B33620

Editor(s):
(1) Dr. Jongwha Chang, University of Texas, College of Pharmacy, USA.

Reviewers:
(1) Zainab Adil Ghani Chabuck, University of Babylon, Iraq.
(2) Sahar El Souda, National Research Center, Egypt.

Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here:
https://www.sdiarticle5.com/review-history/77504

Received 24 September 2021
Accepted 29 November 2021
Published 02 December 2021

ABSTRACT

Multiple sclerosis (MS) is an autoimmune, neuroinflammatory disease which interfere with the central nervous system and damage the myelin sheath and axons. It is mediated by auto-reactive lymphocytes that cross the blood brain barrier cause inflammation, demyelination and axonal loss disturb the communications between the neurons. The exact cause of the MS is not known but it is reported that it may be due to the genetic, environmental factors, viral infections (Epstein Barr virus). There are various approaches for the management of Multiple sclerosis like disease modifying agents are mainly used. Some of the monoclonal antibodies (Ocrelizumab) are approved recently for the management of MS. Due to various unwanted side effects with conventional medicines people are eager to use cost effective medicines with no or less side effects; therefore herbal medicines are best choice for them, they works by different pharmacological actions like reduce oxidative stress, anti-inflammatory, antioxidant effects and others. Mainly used herbal plants like Ginkgobiloba, Salvia officinalis, Nigella sativa.

Keywords: Multiple sclerosis; autoimmune; DMTs; herbal plants.

*Corresponding author: E-mail: drrajeev.rs@gmail.com;
1. INTRODUCTION

Multiple sclerosis is a chronic and progressive autoimmune, inflammatory, neurological disease of the CNS. It destroys the myelin sheath and axons to the varying degrees [1]. It is characterized by inflammation, selective demyelination and gliosis. It targets the Central Nervous System and it is mediated by auto-reactive lymphocytes that cross the blood-brain barrier. These lymphocytes enter the CNS and cause local inflammation resulting in demyelination and axonal loss; by damaging the protective covering of the nerve axons (myelin sheath) cause communication problem between your brain and rest of your body [2]. According to World Health Organization Multiple Sclerosis affects approximately 2.8 million people worldwide, and multiple sclerosis affects the people age between 20-50 years old and it is investigated that females are more prone to the multiple sclerosis than males [3]. The multiple sclerosis characteristic features are common vision loss, pain, fatigue, and impaired coordination, low personal activity-related self-effectiveness, limitation of self-regulatory concepts, socio-demographic factors restrictions, decline employment state, and decrease educational level [4]. People with multiple sclerosis may also develop; muscle stiffness or spasm, paralysis typically in the legs, problems with bladder, bowel, sexual functions, mental changes depression epilepsy. The cause is unknown, but it appears to involve a combination of genetic factors and non-genetic factors such as environmental factors, virus, Metabolism that together result in a self-sustaining autoimmune disorder that leads to recurrent immune system attacks on the central nervous system [5]. All the Multiple Sclerosis treatments try to attempt to improve the neuronal function following Multiple Sclerosis occurs and stop any progression of the disease. The use of Multiple Sclerosis treatments in the early stage of Multiple Sclerosis can induce adverse side effects and can be ineffective at all. The treatments with good results are observed in teenager women where Multiple Sclerosis appears early with relapsing type with few neurons damaged. Multiple Sclerosis decreases life with an average 5–10 years than other healthy ones. There are many treatments and diagnostic procedures of Multiple Sclerosis are in the process of development [3].

Neurologists agree that patients may be grouped into four major categories based on the course of disease.

2. CAUSES

The exact cause of the multiple sclerosis is unknown but some of the investigations show that it may be due to the genetic and environmental factors some other cause are such as viral infections. Most of the studies suggest that multiple sclerosis is immune-genetic viral disease with Epstein Barr Virus [7].

Risk factors are age (most of the time between 20-50 years old), sex (females are more prone to multiple sclerosis than males), family history (genetic susceptibility), certain viral infections like EBV, vitamin D deficiency [8].

Some other risk factors like climate (more in cold areas), autoimmune diseases (higher risks with thyroid diseases, type 1 DM, and IBS), smoking, stress, fatigue, physical injury.

3. PATHOPHYSIOLOGY

Due to etiological factors activated T cells (recognize self-antigen) gain entry into the brain via disruption in the blood brain barrier and macrophages (B cells) enters into the brain from peripheral circulation, production of inflammatory cytokines and free radical species than activated B cells and T cells causes demyelination and destruction of oligodendrocytes and damage the immune system; oligodendrocytes are the cells which are responsible for myelination of axonal nerves now without oligodendrocytes there’s no more myelination to the axon. Formation of plaque cause scarring and destruction of sheath it further interrupt the transmission of impulses. Demyelinated axons scattered irregularly throughout the CNS. The most frequently affected areas are the optic nerves, cerebrum, brain stem, cerebellum, and spinal cord. On early stages oligodendrocytes can heal and remyelination of the axons occurs but over time remyelination will stop and damage will become permanent or irreversible with loss of axons [9,10,11].

4. CURRENT TREATMENT

There is currently no cure for Multiple Sclerosis. The objective of the drugs are to suppress the immune response slow disease progression, limit relapses, decrease long-term neurologic impairment, and manage symptoms while limiting adverse reactions. Disease modifying therapies discussed below are approved for RRMS. Other types of MS are typically treated with the same
Table 1. The categories of multiple sclerosis [6]

| Types                                      | Clinical features                                                                 |
|--------------------------------------------|----------------------------------------------------------------------------------|
| Relapsing/Remitting Multiple Sclerosis (RRMS) | Relapses followed by incomplete remissions, during relapses, symptoms can get more severe |
| Secondary Progressive Multiple Sclerosis (SPMS) | Gradual progression of symptoms and disability over time following a period of RRMS |
| Primary Progressive Multiple Sclerosis (PPMS) | Gradual, progression of symptoms from initial presentation                        |
| Progressive Relapsing Multiple Sclerosis (PRMS) | Gradual symptoms progression over time accompanied by acute attacks of undesired effects |

Table 2. The FDA approved disease modifying drugs with their mode of action, indications, route of administration and dosing frequency of the drug [13,14,15]

| Drugs name                  | Mode of action                                                                 | Indications                                    | Route of administration and dosing frequency |
|-----------------------------|-------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------|
| Ocrelizumab                 | Anti-CD20 mAb                                                                 | First line for RMS, PPSM                       | IV infusion, every 6 months                 |
| Ofatumumab                  | Anti-CD20 mAb                                                                 | First line for RMS                             | SC injection, every 4 weeks                 |
| Natalizumab                 | a4b1 integrin inhibitor                                                       | Second line for RMS and SPMS                  | IV infusion, every 4 weeks                 |
| Alemtuzumab                 | Anti-CD52 mAb                                                                 | Second line for RMS                            | IV infusion, once daily                     |
| Mitoxantrone                | DNA intercalator                                                              | Second line for RMS and SPMS                  | IV infusion, every month or 3 months        |
| Fingolimod                  | Sphingosine-1-phosphate inhibitor                                             | First line RMS                                 | Oral, daily                                 |
| Siponimod                   | Sphingosine 1-phosphate receptor modulator                                    | First line CIS, RMS, SPMS                     | Oral, once daily                            |
| Ozanimod                    | Sphingosine 1-phosphate receptor modulator                                    | First line RMS                                 | Oral, once daily                            |
| Dimethyl fumarate and diroximel | Nuclear factor (erythroiderived 2)–like 2 pathway inhibitor                   | First line RMS                                 | Oral, twice daily                           |
| Cladribine                  | Not fully known                                                               | Second line for RMS                            | Oral, 4-5 days over 2-week treatment courses|
| Teriflunomide               | Dihydroorotate dehydrogenase inhibitor                                        | First line for RMS                             | Oral, once daily                            |
| Glatiramer acetate          | Activates T lymphocytes suppressor cells                                       | First line for RMS                             | SC injection, once daily or 3 times weekly   |
| Interferon β-1a (avonex, rebif) | Suppress expression of inflammatory cytokines                           | First line RMS, CIS                            | IM injection, once weekly                   |
| Peginterferon β-1 (plegrid) | Suppress expression of inflammatory cytokines                                 | First line RMS, CIS                            | SC injection, 3 times weekly                |
| Interferon β-1b (betaseron) | Suppress expression of inflammatory cytokines                                 | First line RMS, CIS                            | SC injection every 2 weeks                 |
| Interferon β-1b (betaseron) | Suppress expression of inflammatory cytokines                                 | First line RMS, CIS                            | SC injection every other day after initial dose |
Table 3. The list of medicinal plants those have an potential to treat Multiple Sclerosis’s patient or decrease the progression of MS

| Common name          | Biological source Family | Active constituents                                                                 | Pharmacological actions                                                                                       | References |
|----------------------|--------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|------------|
| Black cumin          | *Nigella sativa* Ranunculaceae | Seed oils (p-cymene, limonene), thymoquinone and flavonoids                           | Anti-inflammatory, antioxidant, anticholinergic property, enhance remyelation in the CNS                         | [30, 31]   |
| Evening primrose     | *Oenothera biennis* Onagraceae | Fatty acids, phenolic acids, and flavonoids                                          | Anti-inflammatory effects. Anti-asthmatic effects                                                               | [34]       |
| Ginger               | *Zingiber officinale* Zingiberaceae | Phenolic compounds, volatile oils, sesquiterpenes (bisapolene, zingiberol)          | Decrease inflammation, anti-inflammatory effects, antibacterial                                               | [24, 25]   |
| Ginkgo               | *Ginkgo biloba* Ginkgoaceae | Flavonoids like quercetin, kaempferol and diterpene lactones like ginkgolides       | It improves blood flow, reduce oxidative stress, free radicals scavenging activity, less fatigue, improve cognitive functions | [23]       |
| Ginseng              | *Panax ginseng* Araliaceae | Saponins (ginsenosides), phytosterol, carbohydrates                                  | Neuroprotective actions, enhance immunity and CNS activity                                                    | [32, 33]   |
| Grapes               | *Vitis vinifera* Vitaceae | Tannins (catechin, epicatechin and others), flavonoids and procyanidins               | Anti-inflammatory effects, antioxidant activity, improve cognitive functions                                  | [36, 37]   |
| Klamathweed          | *Hypericum perforatum* Hypericaceae | Flavonoids like quercetin, quercitrin, and tannins, essential oils                   | Free radical scavenging activity, block lipid peroxidation, antioxidant activity                              | [28]       |
| Marijuana            | *Cannabis spp.* Cannabaceae | Cannabinoids, tetrahydrocannabinol                                                   | Reduce neuroinflammatory signaling, reduce spasticity and pain                                               | [35]       |
| Marijuana            | *Cannabis spp.* Cannabaceae | Cannabinoids, tetrahydrocannabinol                                                   | Reduce neuroinflammatory signaling, reduce spasticity and pain                                               | [35]       |
| Saffron              | *Crocus sativus* Iridaceae | Volatile oils, tannins, terpenes                                                     | Decrease inflammation, cytotoxic effects                                                                       | [39]       |
| Sage                 | *Salvia officinalis* Lamiaceae | Monoterpenes, flavonoids (apigenin), phenolic acids                                  | Anti-inflammatory effects, antioxidant, improve cognitive functions                                           | [40]       |
| Sudanese frankincense| *Boswellia papyrifera* Burseraceae | Essential oils like alpha pinene, limonene, and n-hexyl acetate                     | Improve visuopatial memory of MS patients                                                                      | [38]       |
| Turmeric             | *Curcuma longa* zingiberaceae | Flavonoids, and other polyphenolic compounds like curcuminoid (curcumin)            | Antioxidant, antimutagenic, antimicrobial, neuroprotective effects                                            | [26, 27]   |
| Valerian             | *Valeriana officinalis* Caprifoliaceae | Alkaloids, terpenes, organic acids, flavones                                      | Gentle sleep aid, anxiolytic, show their actions by binding to the GABA-A receptor                           | [29]       |
drugs, chemotherapy, anti-inflammatory drugs, monoclonal antibodies, immunosuppressive drugs and corticosteroids are mainly used for the management of multiple sclerosis [12].

5. TREATING PROGRESSIVE MULTIPLE SCLEROSIS [16, 17]

Secondary Progressive Multiple Sclerosis: Siponimod44 is a selective S1P modulator that is approved for relapsing forms of Multiple Sclerosis, including active SPMS, meaning patients with secondary progressive multiple, Ocrelizumab, cladribine, and diroximel fumarate can also be used for patients with active Secondary progressive multiple sclerosis.

Primary Progressive Multiple Sclerosis: Ocrelizumab is the only approved DMTs for the management of Primary Progressive Multiple Sclerosis. Dosing is the same as for Relapsing Multiple Sclerosis. Ocrelizumab decreases progression of clinical disability by approximately one-quarter, and improves other clinical and MRI markers of inflammatory and degenerative disease activity in this population.

Some other drugs which are used in multiple sclerosis such as Immunosuppressive agents like azathioprine, methotrexate, cyclophosphamide, other such as Corticosteroids like Methylprednisolone and physical therapy.

5.1 Symptomatic Treatment [18,19]

Dalfampridine is a FDA approved drug which used to improve walking in people who have multiple sclerosis, it works by blocking the potassium channels on the surface of nerve fibres.

6. HERBAL APPROACHES FOR THE MANAGEMENT OF MULTIPLE SCLEROSIS

Nowadays peoples are eager to use treatment which must be cost effective and with lesser adverse effects. Herbal medicines have lesser side effects or no side effects as compared to conventional drug therapies. Upon several investigations it is reported that There are so many medicinal plants which contain different active constituents like flavonoids, alkaloids, saponins, essential oils, tannins etc; belongs to specific families like araliaceae, zingiberaceae, umbelliferae; have the potential to treat or decrease the progression of multiple sclerosis examples like Ginkgo biloba, Salvia officinalis, Cannabis spp., Crocus sativus, Vitis vinifera. These medicinal plants works by different mode of actions like anti-inflammatory effects, antioxidant effects, reduce oxidative stress, free radical scavenging activity and other mechanisms [20,21,22].

7. CONCLUSION

Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system in various ways. It damages the protecting myelin coating and axons, affecting neuron connection. Females are more prone to MS than males. The exact cause of MS is unknown, but according to several reports it may be due to the genetic, environmental factors, viral infections; Epstein-Barr virus. Till now there is no cure for MS and there are various synthetic FDA drugs, monoclonal antibodies which may used for the management of Multiple sclerosis. But due to the undesirable side effects of the synthetic medicines peoples are eager to use cost effective medicines with no or less side effects therefore herbal medicines are best choice for them because herbal medicines have no adverse effects or less side effects as compared to that of conventional medicines. They works by different pharmacological actions like anti-inflammatory, antioxidant, reduce oxidative stress and others.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician 2004;70: 1935–1944.
2. Huang WJ, Chen WW, Zhang X. Multiple sclerosis: Pathology, diagnosis and treatments. Experimental and Therapeutic Medicine. 2017 Jun 1;13(6):3163-6.
3. K. Mohamed Mohamed K. Multiple sclerosis: New insights and trends. Asian Pac J Trop Biomed. 2016;6(5):429–440.

4. Hauser SL, Goodwin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, eds. Harrison’s Principles of Internal Medicine, vol. II, 17th ed. New York: McGraw-Hill Medical. 2008:2611–2621.

5. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288-99.

6. Leary SM, Porter B, Thompson AJ. Multiple sclerosis: Diagnosis and the management of acute relapses’ Postgrad Med J. 2005;81:302–308. DOI: 10.1136/pgmj.2004.029413.

7. Steelman AJ. Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol. 2015;6:520.

8. Marvin M. Goldenberg, ‘Multiple Sclerosis Review’ P&T, march. 2012:37:175-184.

9. Ghasemi N, Shahnaz R, Elham N. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy’ Cell Journal(Yakhteh). 2017;19(1):Apr-Jun (Spring):1-10.

10. Douglas S. Goodin. The pathogenesis of multiple sclerosis’ Clinical and Experimental Neuroimmunology. 2015; 6(Suppl. 1):2–22.

11. Mohamed K, Mohamed K. Multiple sclerosis: New insights and trends. Asian Pac J Trop Biomed. 2016;6(5):429–440.

12. Özlem TAŞKAPILIOĞLU., ‘Recent Advances in the Treatment for Multiple Sclerosis: Current New Drugs Specific for Multiple Sclerosis’ Arch Neuropsychiatry. 2018;55:(Supplement 1): S15–S20.

13. Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: A review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2017;13:871–879.

14. Stasiolek M, Linker RA, Hayardeny L, Bar Ilan O, Gold R. Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study. Immun Inflamm Dis. 2015;3:45–55.

15. Gholamzad M, Masoumeh E, Mehdi S Ardestani. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future’ Springer, Inflammation Research ; 2018. Available:https://doi.org/10.1007/s00011-018-1185-0

16. Suzi B. Claflin, Simon Broadley and Bruce V. Taylor, ‘The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses’ Front. Neurol., 10 January 2019.

17. Ingrid Loma and Rock Heyman, ‘Multiple Sclerosis: Pathogenesis and Treatment’ Current Neuropharmacology. 2011:9(3): 409-416.

18. Lekha Pandit, ‘Multiple sclerosis: Treatment options’ research gate; January 2013. DOI: 10.13140/2.1.2577.9845.

19. Dobson R, Giovannoni G. Multiple sclerosis. European Journal of Neurology. 2019;26:27–40. DOI:10.1111/ene.13819

20. Sina M, Maryam Nazm B, Maryam Ghasemi-Kasman. A Review of Herbal Therapy in Multiple Sclerosis’ Adv Pharm Bull. PMC6311642

21. Ghanavati R. A Review of Possible Herbal Treatment in Multiple Sclerosis in Traditional Persian Medicine’ Iran J Med Sci. 2016;41(3 Suppl):May PMC5103523

22. Song L, Zhou OH, Wang HL, Liao FJ, Hua L, Zhang HF, et al. Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis. Complement Ther Med. 2017;31: 71–81. DOI: 10.1016/j.ctim.2017.02.004.

23. Susan K. Johnson. The Effect of Ginkgo Biloba on Functional Measures in Multiple Sclerosis: A Pilot Randomized Controlled Trial’ Elsevier. 2006;2(1):19-24.

24. Abdullah,Jafarzadeh, ‘Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties’ Journal of Neuroimmunology. 2018; 324(15):54-75.

25. Ghanavati R. A Review of Possible Herbal Treatment in Multiple Sclerosis in Traditional Persian Medicine’ Iran J Med Sci. 2016;41(3 Suppl). PMC5103523.
26. Ghanaatian N. Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets’ J Cell Physiol. 2019;234(8):12237-12248. DOI: 10.1002/jcp.27965

27. Song L, Zhou QH, Wang HL, Liao FJ, Hua L, Zhang HF. et al. Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis. Complement Ther Med. 2017;31:71–81. DOI: 10.1016/j.ctim.2017.02.004.

28. Bowling AC, Ibrahim R, Stewart TM. Alternative medicine and multiple sclerosis: An objective review from an American perspective. Int J MS Care. 2000;2:15-28.

29. Ghanavati R. A Review of Possible Herbal Treatment in Multiple Sclerosis in Traditional Persian Medicine’ Iran J Med Sci. 2016;41(3 Suppl). PMC5103523.

30. Nematollahi M, Majdinasab N, Fakharzade L, Namjooyan F, Latifi S, Pourreza M. The effect of Nigella sativa seeds on the muscle spasticity of lower limbs in patients with multiple sclerosis. Iran J Neurol. 2013;12 Suppl 1:16.

31. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005;5:1749-70.

32. Iriti M, Vitalini S, Fico G, Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules. 2010;15:3517-55.

33. Song L, Zhou QH, Wang HL, Liao FJ, Hua L, Zhang HF. et al. Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis. Complement Ther Med. 2017;31:71–81. DOI: 10.1016/j.ctim.2017.02.004.

34. Ghanavati R. A Review of Possible Herbal Treatment in Multiple Sclerosis in Traditional Persian Medicine’ Iran J Med Sci. 2016;41(3 Suppl). PMC5103523.

35. Bowling AC, Ibrahim R, Stewart TM. Alternative medicine and multiple sclerosis: An objective review from an American perspective. Int J MS Care. 2000;2:15-28.

36. Nihitha Sanka N, Santhipriya RR, Nadendla. An updated review on Anti-Alzheimer’s herbal drugs” Journal of Drug Delivery & Therapeutics. 2018;8(6):360-372.

37. Hauser SL, Goodkin D. Multiple sclerosis and other demyelinating diseases. Harrisons Princ Intern Med. 2001;2:2452-61.

38. Dobson R, Giovannoni G. Multiple sclerosis’ European Journal of Neurology. 2019;26:27–40. DOI:10.1111/ene.13819.

39. Ghazavi A, Mosayebi G, Salehi H, Abtahi H. Effect of ethanol extract of saffron (Crocus sativus L.) on the inhibition of experimental autoimmune encephalomyelitis in C57bl/6 mice. Pak J Biol Sci. 2009;12:690-5.

40. Iriti M, Vitalini S, Fico G, Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules. 2010;15:3517-55.

© 2021 Singh et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/77504